Heavy Ion Therapy Research Integration

Dear Colleagues,

We are pleased to announce a one-week online international specialised course on **Clinical Aspects of Heavy Ion Cancer Therapy Research** which will be held from the 3rd to the 7th of July 2023, online on zoom; see https://indico.cern.ch/event/1248018/

It is **free of charge** and is funded by the European Union's H2020 research and innovation programme through the HITRI*plus* project https://www.hitriplus.eu/.

This school will cover clinical aspects and it is primarily intended for **medical students specialising or who are considering to specialise in oncology as well as clinicians of all levels in radiotherapy and particle therapy.** The course will be delivered by over 35 world-leading clinicians in the field and will focus on head and neck, sarcoma, prostate, liver, pancreas, gynae and rare indications, re-irradiation, innovative methods, organ motion, treatment planning, present and future clinical trials and radiobiology.

The course also includes a "train-the-trainer" session inspired by the very popular "May 2021 HITRIplus Masterclass school". This is based on the professional, open-source, research toolkit **matRad**, tailored to students' and researchers' requirements in treatment planning.

In order to enhance active interaction and participation between students and lecturers as well as networking amongst the students, the school includes online networking students events organised in the evenings.

The school agenda starts at 08:30 CET; however, the lectures will be recorded so they will be immediately available for participants in different time zones.

Please note that details on presentations, recordings as well as zoom connection will be sent to registrants only. Therefore, interested participants are encouraged to register by the 25th of June 2023 on https://indico.cern.ch/event/1248018/registrations/

Please kindly forward this message to medical students as well as clinicians of all levels in radiotherapy and particle therapy who you believe may be interested in this opportunity!

The school organisers would like to take the opportunity to acknowledge the contributions of leading research institutions and hadron therapy facilities, that are collaborating to deliver this course.

SEE ST South East European International Institute for Sustainable Technologies

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008548

Among these are the: South-East European International Institute for Sustainable Technologies (SEEIIST), European Organisation for Nuclear Research (CERN), Heidelberger Ionenstrahl-Therapiezentrum (HIT), National Institutes for Quantum Science and Technology (QST), Centro Nazionale di Adroterapia Oncologica (CNAO), EBG GmbH MedAustron, Helmholtzzentrum fur Schwerionenforschung (GSI), Marburger Ionenstrahl-Therapiezentrum (MIT), Advanced Resource Center for HADrontherapy (ARCHADE), Deutsches Krebsforschungszentrum (DKFZ), Istituto Europeo di Oncologia (IEO), Mayo Clinic, ExtreMe Matter Institute (EMMI), European Network for Light Ion Hadron Therapy (ENLIGHT), Facility for Antiproton and Ion Research in Europe (FAIR), Gunma University Heavy Ion Medical Center, Aristotle University of Thessaloniki(AUTh), University of Texas Southwestern Medical Centre, University of California San Francisco and the University of Malta.

For any further inquiries, please do not hesitate to contact: nicholas.sammut@um.edu.mt or yiota.foka@cern.ch

This project has received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement no: 101008548 - HITRI*plus*.

Best Regards,

The HITRIplus school

Organising Committee

Y. Foka, chair (GSI/SEEIIST)
M. Cirilli (CERN)
P. Fossati (MedAustron)
N. Sammut (Uni. Malta)

Scientific Committee:

P. Fossati chair (MedAustron)
E. Orlandi (CNAO)
S. Harrabi (HIT)
S. Yamada (QST)
Y. Foka (GSI/SEEIIST)
N. Sammut (Uni. Malta)

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008548